Taro admits collusion to end DOJ probe

Taro Pharmaceuticals has entered into a deferred prosecution agreement with the Antitrust Division, but it is costing the generic drugmaker $419 million and an admission that its price-fixing conspiracy impacted more than $500 million worth of commerce.


Get unlimited access to all Global Competition Review content